Company facts
- Headquarters
- Taipei City
- Most recent report
- 6-K, filed Sep 2, 2026
- Filings on record
- 38 filings
- On EDGAR
- CIK 1885680
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer, Emerging growth company
Financials 8 of 12
- 6-K Report a foreign issuer made public elsewhere Sep 2, 2026
- 6-K Report a foreign issuer made public elsewhere Jul 27, 2026
- 6-K Report a foreign issuer made public elsewhere Jun 25, 2026
- 20-F Annual report, foreign issuer May 15, 2026
- 6-K Report a foreign issuer made public elsewhere Nov 26, 2025
- 20-F Annual report, foreign issuer Jun 13, 2025
- 6-K Report a foreign issuer made public elsewhere Dec 6, 2024
- 20-F Annual report, foreign issuer Jul 5, 2024
Prospectuses and Registrations 2
Other 8 of 24
- NT 20-F Apr 30, 2026
- 20-F/A Annual report, foreign issuer, amended Sep 23, 2025
- NT 20-F Apr 30, 2025
- UPLOAD Comment letter from SEC staff Nov 8, 2024
- CORRESP Reply to SEC staff Oct 28, 2024
- 20-F/A Annual report, foreign issuer, amended Oct 28, 2024
- UPLOAD Comment letter from SEC staff Sep 4, 2024
- NT 20-F Apr 30, 2024
Everything here comes from TFA Therapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.